Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Prepping for Passover: ‘Matzah Bake-Off’ prepares for upcoming holiday
Jewish families from the Northwest Suburbs gained hands-on experience Sunday with the food at the center... -
‘We got killed’: Cemetery board weighing next move after referendum fails
The future is uncertain for several Kane County cemeteries after the Campton Township Cemetery District’s referendum... -
A time for change: Meet the class of new mayors in DuPage, Kane suburbs
Mayoral challengers across DuPage and Kane counties had a strong showing in last week’s election. Here’s...